🔎 Trials Near Me

Dachaigh › Leukemia myeloid geur › Texas

Sgrùdaidhean clionaigeach Leukemia myeloid geur ann an Texas

Tha 94 sgrùdaidhean airson Leukemia myeloid geur a’ lorg phàirtichean aig làraichean ann an Texas.

Bailtean ann an Texas

Teacsa sgrùdaidh oifigeil (Beurla)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT05564390

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

  • Children's Medical Center Dallas /ID# 275930, Dallas
A’ fastadhÌre 1
6 Months – 17 Years · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT07306832

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

  • M D Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 50 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT03586609

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

  • The University of Texas MD Anderson Cancer Center /ID# 279402, Houston
A’ fastadhÌre 2/3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT07581002

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • The Don and Sybil Harrington Cancer Center, Amarillo
  • UT MD Anderson Cancer Center, Houston
  • Audie L Murphy VA Hospital, San Antonio
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Texas Children's Hospital, Houston
A’ fastadhSgrùdadh amharc
Aoisean 0 gu 38 · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06131801

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • University of Texas MD Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 12 gu 78 · Gach gnè · Air ùrachadh 29 Sult 2026 · NCT03802695

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
A’ fastadhÌre 2
Aoisean 18 gu 59 · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT05554393

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • M D Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT03629171

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

  • MD Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06548230

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  • Clinical Trial Site, Houston
A’ fastadhÌre 3
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07211958

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Baylor University Medical Center, Dallas
  • Houston Methodist Cancer Center, Houston
  • MD Anderson Cancer Center, Houston
  • agus 2 a bharrachd
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06852222

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  • M D Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT03661307

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT03874052

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

  • M D Anderson Cancer Center, Houston
A’ fastadhÌre 1/2Fàilte do shaor-thoilich fhallain
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT05360160

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT06317649

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

  • M D Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Sult 2026 · NCT03214562

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

  • The University of Texas M. D. Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Sult 2026 · NCT06769490

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

  • MD Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 18 Sult 2026 · NCT06284486

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

  • M D Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 1 agus nas sine · Gach gnè · Air ùrachadh 18 Sult 2026 · NCT03630991

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • Medical City Dallas Hospital, Dallas
  • agus 9 a bharrachd
A’ fastadhÌre 3
6 Months – 21 Years · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT04293562

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

  • MD Anderson, Houston
A’ fastadhÌre 1
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT06786533

Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)

  • Texas Children's Hospital, Houston
  • The Methodist Hospital, Houston
A’ fastadhÌre 1
Suas gu aois 75 · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT06345027

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • The Methodist Hospital Research Institute, Houston
  • The University of Texas MD Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT06824168

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  • The University of Texas MD Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT04996875

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • M D Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT03471260

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

  • M D Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT03683433

A Study of BGB-11417 in Participants With Myeloid Malignancies

  • Md Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT04771130

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

  • The University of Texas MD Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT06616636

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

  • MD Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT06969430

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

  • MD Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 2 gu 18 · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT06191978

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • M D Anderson Cancer Center, Houston
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT05010122

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • M D Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT03383575

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • Medical City Dallas Hospital, Dallas
  • agus 1 a bharrachd
A’ fastadhÌre 3
Aoisean 1 gu 25 · Gach gnè · Air ùrachadh 4 Sult 2026 · NCT07022678

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • Baylor Scott & White Health, Dallas
  • MD Anderson, Houston
A’ fastadhÌre 1/2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 3 Sult 2026 · NCT04588922

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Dallas TX-SOUTHWESTERN, Dallas
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT06652438

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

  • The University of Texas MD Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 18 gu 85 · Gach gnè · Air ùrachadh 26 Lùna 2026 · NCT06834282

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • M D Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT04493164

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

  • The University of Texas M. D. Anderson Cancer Center, Houston
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT06811233

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

  • MD Anderson Cancer Center, Houston
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT06533761

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.